Nasdaq

Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal

Shares of Intercept Pharmaceuticals, Inc. ICPT soared 79.2% after Italy-based pharmaceutical company Alfasigma S.p.A. announced an agreement to acquire Intercept for $19.00 per share in cash. The ...
Nasdaq

Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA

Intercept Pharmaceuticals, Inc. ICPT announced that the FDA issued a complete response letter (CRL) in response to the company’s new drug application (NDA) seeking approval for obeticholic acid (OCA) ...
Business Wire

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood ...
Seeking Alpha

Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties

Intercept Pharmaceuticals, the developer of liver disease drug Ocaliva, has agreed to be acquired by Italian Pharma company Alfasigma in an all-cash deal worth approximately $800 million. Intercept ...
Business Wire

Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product ...